Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:58 PM
Ignite Modification Date:
2025-12-24 @ 4:58 PM
NCT ID:
NCT01931150
Eligibility Criteria:
Inclusion Criteria:
* Patients 18 years or older with underlying diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma including newly diagnosed patient
* Patients must provide written informed consent to participate in the study
* Anticipated initiation of cetuximab treatment with or without additional chemotherapy.
* Able to self-administer topical interventions or provide for another person to apply the topical interventions
Exclusion Criteria:
* Females of childbearing potential who are pregnant or nursing
* Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product
* Patients with pre-existing dermatologic condition affecting the face and chest that would impair assessment of papulopustular rash including dense and/or long facial hair (per investigator discretion)
* Patients currently using prescription and/or over-the-counter topical medications to the face and/or chest who are unwilling to discontinue use during the trial intervention period (day 0 ± 2 days through day 28 ± 2 days)
* Previous or concurrent radiation therapy to head, neck, and chest (i.e. application sites only)
* Previous therapy with cetuximab within 6 months of consent
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01931150
Study Brief:
Protocol Section:
NCT01931150